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Abstract
Protein entrapment and high-performance affinity chromatography were used with zonal elution to examine the changes in
binding that occurred for site-specific probes and various sulfonylurea drugs with normal and glycated forms of human
serum albumin (HSA). Samples of this protein in a soluble
form were physically entrapped within porous silica particles
by using glycogen-capped hydrazide-activated silica; these
supports were then placed into 1.0 cm × 2.1 mm inner diameter columns. Initial zonal elution studies were performed
using (R)-warfarin and l-tryptophan as probes for Sudlow
sites I and II (i.e., the major drug binding sites of HSA), giving
quantitative measures of binding affinities in good agreement
with literature values. It was also found for solutes with multisite binding to the same proteins, such as many sulfonylurea
drugs, that this method could be used to estimate the global
affinity of the solute for the entrapped protein. This entrapment and zonal approach provided retention information with
precisions of ±0.1–3.3% (± one standard deviation) and elution
within 0.50–3.00 min for solutes with binding affinities of 1 ×
104–3 × 105 M−1. Each entrapped-protein column was used for
many binding studies, which decreased the cost and amount
of protein needed per injection (e.g., the equivalent of only
125–145 pmol of immobilized HSA or glycated HSA per injection over 60 sample application cycles). This method can be
adapted for use with other proteins and solutes and should be
valuable in high-throughput screening or quantitative studies
of drug–protein binding or related biointeractions.

Introduction

5833

Diabetes is currently the seventh leading cause of death
in the USA. This disease is characterized by an elevated
level of glucose in blood and exists in two main forms:
type I (juvenile or insulin-dependent) diabetes and type
II (non-insulin-dependent or adult onset diabetes) [1].
One side effect of this disease is the glycation, or nonenzymatic addition, of reducing sugars such as glucose
to amine groups on proteins [2–4]. One protein in blood
that is affected by glycation is human serum albumin
(HSA) [2–8]. HSA is not only the most abundant protein
in human plasma, but it also serves as an important carrier protein for many drugs, fatty acids, and other solutes [9–12]. This protein has two major binding sites for
drugs, which are commonly referred to as Sudlow sites
I and II [10–12]. It is known Sudlow sites I and II, or residues near these sites, may be altered as a result of glycation [2–8, 13–15]. It has also been determined that this
process could potentially alter the binding of some solutes with HSA [2–4, 16], including several sulfonylurea
drugs used to treat type II diabetes [17–21].
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The purpose of this study is to examine a new combination of tools for quickly examining the overall binding
of HSA to drugs and solutes and to determine how such
binding might be affected by glycation. This approach
is based on the use of entrapped proteins and high-performance affinity chromatography (HPAC). HPAC is a
separation method in which a biologically related binding agent is used as the stationary phase on a high-performance liquid chromatography (HPLC) support such
as porous silica [22–25]. This approach has been shown
in many past reports to be a useful method for studying
and characterizing the binding of solutes with biological
agents [22, 26], including the interactions of drugs and
other solutes with proteins such as HSA [23–25]. Advantages of HPAC include its speed, precision, ease of automation, and ability to reuse the same protein preparation for many experiments [23, 25].
In most studies with HPAC, proteins and other binding agents are covalently immobilized onto the surface of a support. However, this immobilization process
can lead to a decrease or loss of activity for the binding
agent owing to multisite attachment, improper orientation, or steric effects [26, 27]. Recently, a noncovalent
immobilization technique has been described for the
physical entrapment of soluble proteins such as HSA
within the pores or near the surface of silica supports
[28]. This approach, as illustrated in Figure 1, makes
use of large particles of mildly oxidized glycogen that
combine with hydrazide-activated silica and entrap soluble proteins on the support while still allowing access
of small solutes and binding targets to these proteins.
This method has been shown in prior work with frontal analysis and a site-selective probe for Sudlow site I,
i.e., (S)-warfarin, to produce immobilized normal HSA

Figure 1. Entrapment of
a protein by reaction of
hydrazide-activated silica
with mildly oxidized
glycogen. Details on this
approach are provided in
the text.
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with essentially full activity and binding constants that
are in good agreement with values that are seen for soluble HSA [28].
This study will examine the combined use of HPAC
columns and protein entrapment to compare the overall
binding of representative drugs and probe compounds
with normal HSA and glycated HSA. The emphasis will
be on the use of such columns in zonal elution studies
[23–25] to provide a relatively fast means for examining
the binding of the entrapped proteins to injected targets.
This method will first be evaluated by using it to compare the binding of normal HSA versus glycated HSA to
(R)-warfarin and l-tryptophan (i.e., site-selective probes
for Sudlow sites I and II, respectively) [10, 29, 30]. This
approach will then be extended to studies examining the overall binding of several sulfonylurea drugs
to the same protein samples. These results will be compared with those obtained by other methods for similar systems and should provide valuable data regarding
the use of protein entrapment and HPAC for comparing the binding properties of normal and modified proteins. The same data should help illustrate the potential
for this combined approach in high-throughput screening of drug–protein interactions.
Experimental
Chemicals
p-Periodic acid (periodic acid reagent, or H5IO6), glycogen (from bovine liver), HSA (Cohn fraction V, 99%
globulin free, 99% fatty acid free), glycated HSA (95%
lyophilized, lot no. 115K6108, prepared in vitro and con-
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taining 1.8 mol hexose per mole of HSA), (R)-warfarin, l-tryptophan, acetohexamide, gliclazide, and tolbutamide were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Nucleosil Si-300 silica (300-Å pore size, 7-μm
particle diameter) was purchased from Macherey-Nagel
(Düren, Germany). Reagents for the micro bicinchoninic
acid (BCA) protein assay were from Pierce (Rockford, IL,
USA). Other chemicals were of the purest grades available. Econo-Pac 10 DG disposable 10-mL desalting columns were obtained from Bio-Rad Laboratories (Hercules, CA, USA). All solutions were prepared using water
from a NANOpure purification system (Barnstead,
Dubuque, IA, USA) and filtered through 0.20-μm GNWP
nylon membranes from Millipore (Billerica, MA, USA).
Instrumentation
The chromatographic system consisted of a JASCO
(Tokyo, Japan) PU-980i intelligent HPLC isocratic
pump, a Rheodyne (Cotati, CA, USA) Advantage PF
ten-port valve, and a JASCO UV-975 UV/vis detector.
The detection wavelengths were as follows: 304 nm, (R)warfarin; 280 nm, l-tryptophan; 205 nm, sodium nitrate;
248 nm, acetohexamide; 226 nm, gliclazide; and 250 nm,
tolbutamide. Data were collected using an interface and
software from National Instruments (Austin, TX, USA).
The temperature of the columns and mobile phases was
controlled using a PolyScience (Buffalo Grove, IL, USA)
circulating water bath and a water jacket from Alltech
(Deerfield, IL, USA). All columns were packed using
an HPLC column slurry packer from Alltech. The chromatographic data were analyzed using Peakfit 4.12 (Jandel Scientific Software, San Rafael, CA, USA).
Methods
The overall scheme used for protein entrapment was
based on a procedure reported in [28] using normal
HSA as a model; the same method was found to entrap
glycated HSA in preliminary studies in this prior report.
The oxidation of glycogen was performed in pH 5.0
buffer containing 20 mM sodium acetate and 15 mM
sodium chloride. A 4.0 mL solution was prepared by
dissolving 135 mg of periodic acid and 17 mg of glycogen in this buffer. The resulting solution was covered in aluminum foil, because of the light sensitivity
of periodic acid, and was shaken at room temperature
for 12–24 h. After oxidation, the glycogen was separated
from the remaining periodic acid by using an Econo-Pac
10DG disposable desalting column and pH 5.0, 0.10 M
potassium phosphate buffer as the mobile phase. The
resulting solution of oxidized glycogen had a concentration of approximately 4.2 mg/mL, a final volume of
around 4.0 mL, and approximately 0.5% oxidation of the
glucose units in glycogen [28]. This solution was stored
in pH 5.0, 0.10 M phosphate buffer at 4 °C.
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The normal HSA and glycated HSA supports were
prepared under the same immobilization conditions.
A 50 mg/mL stock solution of each protein was first
prepared in pH 5.0, 0.10 M potassium phosphate buffer. The starting support, Nucleosil Si-300, was converted into a hydrazide-activated form according to a
previous procedure [31]. To create the entrapped-protein support, 80 mg of hydrazide-activated silica was
combined with 160 μL of the protein solution. This
mixture was sonicated under a vacuum for 15 min to
remove any air trapped within the support’s pores. A
380-μL portion of the oxidized glycogen solution was
then added, and this mixture was shaken at room temperature for 12 h. During the final hour of the reaction,
200 μL of a 2 mg/mL oxalic dihydrazide solution in
pH 5.0, 0.10 M phosphate buffer was added to the reaction mixture to combine with any remaining aldehyde
groups on the glycogen. After immobilization, the support was washed several times with pH 7.4, 0.067 M
potassium phosphate buffer. A control support was
prepared in the same manner by using only pH 5.0,
0.10 M phosphate buffer in place of the protein solution during the entrapment step [28]. The protein content of each final support was determined in triplicate
by using a micro BCA assay, with soluble HSA or glycated HSA being used as the standard and the control
support being used as a blank.
All supports were downward slurry-packed into separate 1.0 cm × 2.1 mm diameter stainless steel columns
at 27.6 MPa (4,000 psi) using pH 7.4, 0.067 M potassium
phosphate buffer as the packing solution. The columns
were stored at 4 °C in this packing solution. The sample solutions for the chromatographic studies were prepared in pH 7.4, 0.067 M potassium phosphate buffer,
which was also used as the mobile phase. Stock solutions with a concentration of 30 μM (R)-warfarin, or
100 μM l-tryptophan, acetohexamide, gliclazide, or tolbutamide were prepared in the same pH 7.4 buffer and
diluted with this pH 7.4 buffer to give 10 μM working
samples for these analytes; these sample concentrations
were found to be sufficiently low compared with the column’s overall binding capacity to provide linear elution
conditions during the retention factor measurements.
A 20-μL volume of each 10 μM sample solution was
injected in triplicate onto the entrapped-protein columns and the control column at 37 °C. Flow rates of 0.11.0 mL/min were used to examine the binding of each
analyte to the columns. The void time of each column
was determined by making triplicate 20-μL injections of
25 μM sodium nitrate in the presence of pH 7.4, 0.067 M
potassium phosphate buffer at all the flow rates tested.
Sodium nitrate has routinely been used in the past as
a void volume marker for columns containing covalently immobilized HSA and glycated HSA, as well as
with columns containing hydrazide-activated silica,
and has been found to give good agreement with calcu-
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lated void volumes based on the known packing densities and porosities of the corresponding supports [19–
21, 23, 25, 28–31]. The void time of the system was determined by repeating the injections of sodium nitrate but
using a zero-volume union in place of the column. A fit
to an exponentially modified Gaussian curve was used
to determine the central moment of each peak for the
calculation of retention factors.
Results and discussion
General properties of entrapped HSA and glycated
HSA columns
The entrapment supports were found through a BCA
protein assay to contain 37 (± 1) mg HSA per gram of
silica, or 32 (± 2) mg glycated HSA per gram of silica,
where the values listed in parentheses throughout this
article represent a range of ± one standard deviation.
These supports were packed into 1.0 cm × 2.1 mm inner
diameter columns, resulting in a total protein content in
terms of moles (m Ltotal) of 8.7 nmol or 7.5 nmol (i.e., 500
μg or 580 μg) for the HSA and glycated HSA (note these
values were estimated by using a packing density of
0.45 g/cm3 for the support material, as reported by the
manufacturer, and a molar mass for HSA and glycated
HSA of 66.5 kDa). The columns were found to be stable
and give reproducible retention factors over the course
of more than 60 sample injection cycles and approximately 4 months of operation. Because each entrapped
protein sample was used for many binding studies, this
resulted in a decrease in the cost and overall amount of
protein needed per injection. For instance, the equivalent of only 125-145 pmol (8.3-9.7 μg) of immobilized
HSA or glycated HSA was used per injection when
employed over the course of 60 application cycles.
These columns were initially evaluated by using
zonal elution as a rapid means for obtaining estimates
of binding affinities for injected probe compounds or
solutes with the entrapped proteins. Figure 2 provides
some typical chromatograms that were obtained for
(R)-warfarin and l-tryptophan on these columns. When
compared with the control column containing no protein, both the normal HSA column and the glycated
HSA column showed markedly increased retention
for both probe compounds. (R)-warfarin, which has an
association equilibrium constant of roughly 2 × 105–3 ×
105 M-1 for normal HSA [29], was eluted within 5-6 min
at 0.5 mL/min from both types of entrapped-protein columns and within 2.5-3 min from the same columns at 1.0
mL/min. l-tryptophan, which has a tenfold lower association equilibrium constant of approximately 1 × 104–2
× 104 M-1 for normal HSA [30], was eluted in only 1.0-1.5
min at 0.5 mL/min from both types of entrapped-protein columns and within 0.50-0.75 min at 1.0 mL/min.

Figure 2. Chromatograms obtained for the injection of a (R)warfarin or b l-tryptophan as a site-selective probe onto a control column containing no entrapped protein or columns containing entrapped normal human serum albumin (HSA) or
glycated HSA. These results were obtained at 0.50 mL/min.
Other conditions are given in the text.

Reproducible retention factors and stable binding characteristics were obtained on these columns for triplicate injections obtained over five flow rates ranging
from 0.1 to 1.0 mL/min, with retention factors showing
only random variations of ±4% overall for (R)-warfarin
and ±11% for l-tryptophan. The precisions of the retention factors measured at individual flow rates for the
same solutes ranged from ±0.4 to ±1.1% and from ±0.6
to ±3.3%, respectively, with the precision increasing as
slower flow rates and longer residence times were used.
Binding of (R)-warfarin with entrapped HSA and
glycated HSA
The next part of this study used HPAC and the columns
containing entrapped samples of normal HSA or glycated HSA to evaluate the binding of these columns to
(R)-warfarin as a probe for Sudlow site I (i.e., the warfarin–azapropazone site) [10, 29, 32]. This drug (see Figure S1 for the structure) has been previously shown to
bind to both normal and glycated HSA in a site-selective
manner. The association equilibrium constants at pH 7.4
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and 37 °C for these interactions have been estimated by
various methods for normal HSA [2, 29, 30, 32–34] and
by frontal analysis for in vitro glycated HSA [2], thus
providing reference values for this current study for the
evaluation of the entrapped-protein columns.
In the zonal elution approach that was used in this
study, the specific retention factor (k) was determined
for an injected drug or solute on a given protein column
after correcting for the effect of any nonspecific interactions with the support on the total retention, e.g., a correction for (R)-warfarin which was only 2.5-2.6% of the
total retention seen on the entrapped protein columns;
this approach was adequate for the current study, but
a more thorough analysis of the nonspecific interactions
could be obtained in future work through frontal analysis. The use of the specific retention factor provided a
relatively fast and easy way of measuring and comparing the level of binding for each injected solute on the
entrapped-protein columns. For more detailed studies
of binding, the resulting value of k due to the entrapped
protein could also be directly related to the global affinity constant (nKa′) of the solute with the immobilized
protein, as represented by the general expression in
Equation 1 for any group of independent binding sites
[23, 25]:
Single-site or multisite binding: k =

(nK′a mLtotal )
VM

(1)

where mLtotal again represents the total number of moles
of protein, and VM is the column void volume [23].
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It is important to note in Equation 1 that nKa′ is a
number-weighted sum of the association equilibrium
constants for all binding sites of the solute on the immobilized protein, as indicated by Equation 2 for a system
with multiple, independent binding sites [23, 25]:
nKa’ = ∑ (ni Kai )

(2)

In Equation 2, ni represents the relative number of
moles of binding site i for a given solute per mole of
protein, and Kai is the association equilibrium constant
for the same site and solute. If only a single type of binding site for a drug or solute is present and essentially all
of the immobilized protein is present in an active form
(i.e., as could occur for an entrapped but noncovalently
immobilized protein), Equation 1 can be rewritten as
Equation 3:
Single-site binding:

k =

(KamLtotal )
VM

(3)

In this specific case, n = 1 and nKa’ is now given by Ka,
the association equilibrium constant for the solute at its
binding site on the protein.
Table 1 summarizes the specific retention factors that
were measured for (R)-warfarin on the columns containing entrapped normal HSA and glycated HSA. To
correct for differences in the protein content of these
supports and to allow a direct comparison of their
retention values, the specific retention factors were normalized by dividing them by each support’s total protein content [35, 36]. When these normalized retention

Table 1. Retention factors and global affinity constants measured for (R)-warfarin and l-tryptophan on columns containing
entrapped normal human serum albumin (HSA) or glycated HSA
Type of HSA
and solute
Normal HSA
(R)-warfarin
l-tryptophan
Glycated HSA
(R)-warfarin
l-tryptophan

Specific retention
factor, k a

Normalized retention factor,
k/(protein content) b

Global affinity,
nKa′ (M-1) c

84.7 (± 0.5)
5.7 (± 0.2)

2.29 (± 0.06)
0.15 (± 0.01)

2.9 (± 0.1) × 105
1.8 (± 0.1) × 104

78.5 (± 0.8)
14.22 (± 0.03)

2.45 (± 0.08)
0.44 (± 0.01)

3.1 (± 0.1) × 105
5.5 (± 0.2) × 104

The values in parentheses represent a range of ± one standard deviation, as based on triplicate measurements made over five flow
rates (n = 15). As indicated in the text, the same range of flow rates was used to initially evaluate the reproducibility and stability
of these columns over a range of operating conditions but gave no significant differences in the measured retention factors.
a. The specific retention factor was obtained by taking the difference between the overall retention factor on an entrapped-protein
column and the retention factor due to nonspecific interactions measured for the same solute on the control column, with the
latter value being 2.13 (± 0.05) for (R)-warfarin and 0.77 (± 0.03) for l-tryptophan.
b. The normalized retention factors were calculated by dividing the specific retention factors by the measured total protein content
for each given support, using values of 37 (± 1) mg HSA per gram or 32 (± 2) mg glycated HSA per gram.
c. The value of nKa′ was estimated by using Equation 1 along with the specific retention factor (k) for each solute, the measured void
volume (V M), and the number of moles of protein in the column (m Ltotal). The value used for VM was 29 μL and m Ltotal was 8.7
nmol or 7.5 nmol for the normal HSA or glycated HSA columns, respectively; details on the determination of VM and m Ltotal are
provided in the text.
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factors were compared, no significant difference at the
95% confidence level (i.e., the confidence level used for
all comparisons in this study) was seen in the values for
(R)-warfarin on the columns containing normal HSA
and glycated HSA. These results indicated the level of
glycation present in this case did not have an observable effect on the binding of (R)-warfarin with HSA at
Sudlow site I. These results are consistent with previous data and conclusions obtained when frontal analysis was used to compare covalently immobilized normal HSA with in vitro glycated HSA that had levels of
modification for the glycated HSA that were similar or
equivalent to those used in the current study [2].
Using the fact that (R)-warfarin has only one major
binding site on normal HSA and glycated HSA, and
that most of these entrapped proteins should have
been active, we used the retention data to further estimate and compare the association equilibrium constants for this interaction. These results are also provided in Table 1. The K a of 2.9 (± 0.1) × 105 that was
calculated from the zonal elution data for (R)-warfarin
with normal HSA was in good agreement with previously reported values of 2.1× 105–3.3 × 105 M-1 for this
interaction under the same temperature conditions [2,
29, 30, 32–34]. The K a of 3.1 (± 0.1) × 105 M-1 obtained for
(R)-warfarin with the glycated HSA was also consistent
with prior estimates of 2.3 (± 0.3) × 105–to 2.7 (± 0.3) ×
105 M-1 that have been made by frontal analysis for similar preparations of this protein [2]. In addition, the calculated K a values did not show any significant difference between the normal HSA and glycated HSA columns, as noted in the prior studies [2].
Binding of l-tryptophan with entrapped HSA and glycated HSA
The same columns as described in the previous section
were examined for their binding to l-tryptophan as a
probe for Sudlow site II (i.e., the indole–benzodiazepine
site) [10, 30, 37]. Like (R)-warfarin, this solute (see Figure S1 for the structure) is known to bind to both normal and glycated HSA in a site-selective manner [2, 10,
30]. The association equilibrium constant for the binding of l-tryptophan with normal HSA has also been
determined by various techniques at 37 °C [30, 34, 37,
38], and the binding of this solute under the same conditions with in vitro glycated HSA has been previously
examined by frontal analysis [2], again providing values
that could be used to evaluate the performance of the
entrapped-protein columns.
The results from the zonal elution studies that were
obtained for l-tryptophan are included in Table 1.
Unlike the data acquired for (R)-warfarin, the normalized retention factors that were calculated for l-tryptophan showed a large change when going from normal
HSA to glycated HSA, even after a correction had been
made for differences in the total protein content of the
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columns. The normalized retention factor for l-tryptophan on the entrapped glycated HSA column was
roughly three times higher than that for l-tryptophan
on the column containing normal HSA. This difference
was significant at the 95% confidence level. The value of
nK a′ between these two columns increased by the same
factor and was again significant at the 95% confidence
level. These results clearly indicated that the glycation
of HSA did affect the binding of l-tryptophan to Sudlow
site II, as was concluded in a previous study [2].
Given the fact that l-tryptophan has only one major
binding site on HSA, the global affinity measured for this
solute was assumed to represent the association equilibrium constant for this interaction. The average K a of 1.8
(± 0.1) × 104 M-1 that was estimated by this approach for
l-tryptophan with the entrapped normal HSA was in
good agreement with previous values of 1.1 × 104–2.4
× 104 M-1 that have been determined by other methods
for this interaction at 37 °C [2, 30, 34, 37–39]. The K a of
5.5 (± 0.2) × 104 M-1 measured for l-tryptophan with the
entrapped glycated HSA also fit within the range of 5.2
× 104–6.4 × 104 M-1 that has previously been measured
by frontal analysis at 37 °C with in vitro glycated HSA
preparations having similar levels of modification [2].
Binding of sulfonylurea drugs to entrapped HSA and
glycated HSA
The final stage of this work used the entrapped HSA
and glycated HSA columns to screen and compare the
binding of various sulfonylurea drugs to these proteins.
The sulfonylurea drugs considered in this study were
acetohexamide, gliclazide, and tolbutamide (see the
structures in Figure 3). Unlike (R)-warfarin and l-tryptophan, these sulfonylurea drugs are known to bind to
both Sudlow site I and Sudlow site II of normal HSA
and glycated HSA, as well having a set of weaker interaction sites with these proteins [2, 17, 19–21]. Thus, for
these drugs the use of retention factors to describe protein interactions would be expected to reflect the contributions of multiple binding regions, as indicated by
Equations 1 and 2, rather than a single binding site, as
described by Equation 3.
Some typical chromatograms obtained in these studies are shown in Figure 4. As noted earlier with (R)-warfarin and l-tryptophan, each of the sulfonylurea drugs
exhibited a large difference in retention between the
entrapped-protein columns and the control column.
These drugs were eluted within 1.1-5.0 min at 0.5 mL/
min and within 0.6-2.5 min at 1.0 mL/min from the columns containing the entrapped proteins. The measured
retention factors had good reproducibility over flow
rates ranging from at least 0.1 to 1.0 mL/min, with values
varying by only ±3%, ±6%, or ±8% for acetohexamide,
gliclazide, and tolbutamide, respectively. The retention
factors measured at individual flow rates for the same
drugs ranged from ±0.1 to ±0.6%, from ±0.1 to ±1.7%,
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Figure 4. Chromatograms obtained for acetohexamide on a
control column containing no entrapped protein or on columns containing entrapped normal HSA or glycated HSA.
These results were obtained at 0.50 mL/min. Other conditions
are given in the text.

Figure 3. Basic structure of a sulfonylurea drug and the structures of the specific sulfonylurea drugs that were examined in
this study.

and from ±0.2 to ±0.7%, respectively, and tended to
improve as the flow rate was decreased and the residence time was increased.
Table 2 provides the specific retention factors that
were measured for each of the sulfonylurea drugs on
the normal HSA and glycated HSA columns. Normalized retention factors that corrected for differences in
the protein content of these columns were also calculated (see the footnote in Table 2). These sulfonylurea
drugs showed an increase of 55-77% in the normalized
retention factors for the glycated HSA column compared with the normal HSA column. This increase in
the normalized retention factor was in agreement with
previously reported trends noted for these sulfonylureas when covalently immobilized samples of normal
HSA and a preparation of in vitro glycated HSA similar
to that used in the current study were used [18]. These
trends also agreed with those seen in separate ultrafiltration studies using physiological levels of normal HSA
and in vitro glycated HSA [20, 21, 40].
These retention data were further used to estimate
the global affinities of each sulfonylurea drug with the
entrapped samples of HSA and glycated HSA, as given in
Table 2. In this case, it was known from prior studies that
all of these drugs had two sets of binding sites on HSA

(i.e., moderate-to-high affinity sites and weak binding
regions), with most of this binding being attributed to one
or two moderate-to-high affinity sites [17, 19–21]. Thus,
the global affinities shown in Table 2 would be predicted
from Equation 2 to represent a number-weighted sum of
the association equilibrium constants for these sites; note
that zonal elution competition studies with probes such
as (R)-warfarin and l-tryptophan could also be employed
to obtain information on the affinities at specific binding
sites [17, 19–21, 23]. The relative trends shown in Table 2
for these results were the same as noted for the normalized retention factors, as would be expected from Equation 1 because these two sets of values were directly proportional to each other.
The global affinities given in Table 2 compared well
with those predicted by Eqs. 1 and 2 when calculating
such results using previous binding capacities and association equilibrium constants obtained by frontal analysis, or a combination of these results with site-selective binding constants that were obtained by zonal elution at the higher-affinity sites for sulfonylurea drugs
with covalently immobilized samples of normal HSA
and in vitro glycated HSA [17, 19–21]. In each case, most
of the calculated global affinity (i.e., 92-99% for acetohexamide, 82-92% for gliclazide, and 92-98% for tolbutamide) was due to the contributions of the moderateto-high binding regions for these drugs with HSA (i.e.,
Sudlow sites I and II).
Because the zonal elution approach used in this study
employed direct measurements of retention to estimate global affinities, the precision of this approach was
much better than when combining association equilibrium constants and binding capacity results to calculate global affinities. For instance, the global affinities
obtained by using data from prior frontal analysis and
zonal elution studies [17, 19–21] had typical final preci-
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sions of ±20-50%, as based on error propagation. In contrast, the global affinities in Table 2 that were measured
directly by zonal elution for the entrapped-protein columns had precisions of ±3-10%.
Another potential advantage of using entrapped proteins to measure global affinities was that little or no loss
of activity should have occurred during the immobilization process [26, 28]. This feature is essential if zonal elution data are to be used directly for determining binding
constants [23, 25] and has made this approach generally
impractical for use with covalent immobilization techniques because the loss of protein activity is common
during such coupling methods [23, 25, 26]. For instance,
it was estimated from previous frontal analysis data [17,
19–21] that a combined loss in activity of 35-60% for acetohexamide, 45-59% for tolbutamide, and 75-80% for
gliclazide occurred at Sudlow sites I and II when normal HSA and glycated HSA that had been covalently
immobilized by the Schiff base method were used [17,
19–21]. On the basis of prior work with (R)-warfarin and
l-tryptophan, it is expected that a similar or even larger
decrease in the activity for HSA might occur when other
covalent immobilization methods are used [35, 36].
Concluding remarks
This report examined the use of entrapment and
HPAC-based zonal elution studies to examine the
changes in binding and overall affinity that occurred
for site-specific probes and various sulfonylurea drugs
with normal HSA versus glycated HSA. The columns
created by entrapment gave retention factors with precisions of ±0.1-3.3% over the course of more than 4
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months of operation. The compounds retained on the
entrapped-protein columns had elution times of less
than 2.5-3.0 min at 1.0 mL/min for solutes with affinities as high as 2× 105–3 × 105 M-1, e.g., as represented
by (R)-warfarin on the normal HSA and glycated HSA
columns, and less than 0.50-0.75 min for solutes with
affinities down to 1× 104 –2 × 104 M-1, e.g., as seen for
l-tryptophan on the normal HSA column. The ability to
use these columns over many experiments produced
a system that required the equivalent of less than 125145 pmol of immobilized protein per injection over
60 application cycles. All of these characteristics are
attractive for using such an approach in biointeraction
studies and in the high-throughput screening of drug–
protein binding.
The ability of this method to provide a rapid, quantitative measure of binding affinity was also examined.
In the case of solutes having a single major binding site
on HSA, this approach could be used to determine the
association equilibrium constant for the injected solutes
with the entrapped proteins. For instance, the binding
constants determined by this approach for (R)-warfarin at Sudlow site I and for l-tryptophan at Sudlow site
II were in good agreement with results reported with
other techniques for normal HSA or glycated HSA [2,
29, 30, 32–34, 37–39]. For solutes with multisite binding,
this method could be used to estimate the global affinity
of the solute for the entrapped protein. This was illustrated by using this approach to examine and compare
the global affinities of various sulfonylurea drugs with
normal HSA and glycated HSA. The values obtained
again showed good agreement with trends and results
that were predicted by other techniques and with use of
similar protein preparations [17–21, 40].

Table 2. Retention factors and global affinity constants measured for sulfonylurea drugs on columns containing entrapped
normal HSA or glycated HSA
Type of HSA
and drug
Normal HSA
Acetohexamide
Gliclazide
Tolbutamide
Glycated HSA
Acetohexamide
Gliclazide
Tolbutamide

Specific retention
factor (k)

Measured global affinity,
nKa′ (M-1) a

Estimated global
affinity, nKa′ (M-1) b

46.5 (± 0.1)
17.1 (± 0.2)
30.8 (± 0.1)

1.6 (± 0.1) × 105
5.8 (± 0.2) × 104
1.0 (± 0.1) × 105

1.6 × 105–1.7 × 105
5.2 × 104–7.9 × 104
1.0 × 105–1.1 × 105

62.7 (± 0.1)
23.4 (± 0.1)
47.0 (± 0.2)

2.5 (± 0.1) × 105
9.1 (± 0.3) × 104
1.9 (± 0.1) × 105

1.6 × 105–1.8 × 105
6 × 104–12 × 104
1.1 × 105–1.5 × 105

The values in parentheses represent a range of ± one standard deviation, as based on triplicate measurements made over five
flow rates (n = 15). The specific retention factors and values for nKa′ were determined in the same manner as described in
Table 1. In obtaining the specific retention factors, we found the retention factor measured for nonspecific interactions by these
drugs on the control column were 0.42 (± 0.04) for acetohexamide, 0.95 (± 0.10) for gliclazide, and 0.39 (± 0.04) for tolbutamide.
a. The nKa′ values measured for the normal HSA column were determined by using the following normalized retention factors:
1.26 (± 0.03) for acetohexamide, 0.46 (± 0.01) for gliclazide, and 0.83 (± 0.02) tolbutamide. The nKa′ values for the glycated
HSA column were found by using the following normalized retention factors: 1.96 (± 0.06) for acetohexamide, 0.73 (± 0.02) for
gliclazide, and 1.47 (± 0.05) for tolbutamide.
b. These values were calculated by using frontal analysis and zonal elution data from [17, 19–21], as described in the text.
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b i n d i n g s t u d i e s w i t h e n t r a pp e d n o r m a l o r g l y c a t e d

These results indicate the entrapped-protein columns
could be used directly with HPAC and zonal elution to
estimate and compare binding constants or global affinities for normal and modified proteins such as HSA and
glycated HSA. Obtaining these quantitative estimates of
affinities was made possible by the fact the entrapped
protein was immobilized in a form that retained all or
most of its original activity [28]. This feature, in turn,
allowed the value of Ka or nKa′ to be determined from
the measured retention factors of solutes if the protein content of the support was also known. This direct
approach based on zonal elution was not possible in the
past when covalent immobilization methods were used
because of the loss of activity that occurs for some of the
immobilized protein and the possible presence of different degrees of inactivation at separate regions on an
immobilized protein [26]. Instead, retention measurements have been used in the past to make only relative
comparisons of activity [18, 23, 35, 36], or more complicated and time-consuming methods based on frontal
analysis or zonal elution plus competition experiments
have been required to obtain binding constants that
can be measured in a manner independent of the actual
amount of active binding sites [2, 17, 19–21, 23–25].
The combined speed and ease of using zonal elution with the entrapped forms of proteins should make
this approach attractive for clinical and pharmaceutical applications that may benefit from high-throughput
screening or quantitative studies of binding between
proteins and small soluble targets. For instance, the
shifts in normalized retention factors and affinities that
were measured when entrapped normal HSA and glycated HSA were used are of potential interest in examination of how glycation may affect the protein binding of sulfonylurea drugs in blood [17–21]. Such information, in turn, may help clinicians to avoid issues with
using either too low or too high of a dose for these drugs
when treating diabetes, which could lead to the undesired side effects of inadequate glucose control or hypoglycemia, respectively [19, 41]. The same general methods as used in this study could be adapted for other proteins and solutes or for comparing different protein populations and biointeraction systems of interest in clinical, pharmaceutical, or biomedical research.
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